Lantuejoul, Sylvie, et al. "PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee." Journal of Thoracic Oncology 15.4 (2020): 499-519.
Davis, Andrew A., and Vaibhav G. Patel. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. Journal for immunotherapy of cancer 7.1 (2019): 278.
Prince, Spasenija Savic, and Lukas Bubendorf. "Predictive potential and need for standardization of PD-L1 immunohistochemistry." Virchows Archiv 474.4 (2019): 475-484.
Tsao, MING SOUND, et al. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. Aurora, CO: International Association for the Study of Lung Cancer (2017).
Lawson, Nicola L., et al. "Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies." Modern Pathology 33.4 (2020): 518-530.